42.13
0.49%
0.26
Springworks Therapeutics Inc stock is traded at $42.13, with a volume of 266.12K.
It is up +0.49% in the last 24 hours and up +37.41% over the past month.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
See More
Previous Close:
$41.87
Open:
$41.8
24h Volume:
266.12K
Relative Volume:
0.25
Market Cap:
$3.06B
Revenue:
-
Net Income/Loss:
$-301.06M
P/E Ratio:
-8.6509
EPS:
-4.87
Net Cash Flow:
$-248.01M
1W Performance:
+2.07%
1M Performance:
+37.41%
6M Performance:
+7.14%
1Y Performance:
+31.90%
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Name
Springworks Therapeutics Inc
Sector
Industry
Phone
203-883-9490
Address
100 WASHINGTON BOULEVARD, STAMFORD, CT
Compare SWTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
42.08 | 3.06B | 0 | -301.06M | -248.01M | -4.44 |
VRTX
Vertex Pharmaceuticals Inc
|
461.00 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
251.31 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.50 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-20-24 | Initiated | Evercore ISI | Outperform |
Feb-05-24 | Initiated | Guggenheim | Buy |
Dec-01-22 | Initiated | BofA Securities | Buy |
Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
May-05-20 | Initiated | Barclays | Overweight |
Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
Dec-04-19 | Initiated | H.C. Wainwright | Buy |
Oct-08-19 | Initiated | Cowen | Outperform |
Oct-08-19 | Initiated | Goldman | Buy |
Oct-08-19 | Initiated | JP Morgan | Overweight |
Oct-08-19 | Initiated | Wedbush | Outperform |
View All
Springworks Therapeutics Inc Stock (SWTX) Latest News
Walleye Capital LLC Grows Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Fmr LLC Boosts Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Intech Investment Management LLC Acquires New Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Dynamic Technology Lab Private Ltd Buys Shares of 13,717 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Ally Bridge Group NY LLC Invests $7.30 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times
SpringWorks Therapeutics to Present at Evercore ISI HealthCONx Conference | SWTX Stock News - StockTitan
Massachusetts Financial Services Co. MA Boosts Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
(SWTX) Investment Analysis - Stock Traders Daily
SpringWorks Therapeutics' SWOT analysis: stock shows promise amid challenges - Investing.com
Alpha DNA Investment Management LLC Makes New $411,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
GSA Capital Partners LLP Makes New $209,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
Eagle Asset Management Inc. Sells 54,366 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading 8.1% HigherShould You Buy? - MarketBeat
SpringWorks Therapeutics Inc. (SWTX): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Evercore ISI Begins Coverage on SpringWorks Therapeutics (NASDAQ:SWTX) - Defense World
SpringWorks started at outperform by Evercore ahead of FDA decision - MSN
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect? - MSN
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Position Boosted by Victory Capital Management Inc. - MarketBeat
SpringWorks Therapeutics: Q3 Earnings Snapshot - AOL
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
Wedbush Has Negative Forecast for SWTX FY2024 Earnings - Defense World
When (SWTX) Moves Investors should Listen - Stock Traders Daily
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report - Yahoo Finance
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results - Simply Wall St
FY2024 Earnings Forecast for SWTX Issued By HC Wainwright - MarketBeat
Wedbush Has Negative Outlook for SWTX FY2024 Earnings - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Quarterly 10-Q Report - Quartzy
Los Angeles Capital Management LLC Boosts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
HC Wainwright Issues Pessimistic Forecast for SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price - Defense World
SpringWorks Therapeutics (NASDAQ:SWTX) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Principal Financial Group Inc. Has $29.43 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highli - GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down on Analyst Downgrade - Defense World
SpringWorks Therapeutics Q3 2024 Results Overview - TipRanks
SpringWorks Therapeutics Inc (SWTX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
SpringWorks Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
HC Wainwright Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $74.00 - MarketBeat
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
SpringWorks Therapeutics to Present at Jefferies London Healthcare Conference | SWTX Stock News - StockTitan
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study - Yahoo Finance
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
SOPHiA GENETICS (NASDAQ:SOPH) vs. SpringWorks Therapeutics (NASDAQ:SWTX) Financial Review - Defense World
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q - GuruFocus.com
Springworks Therapeutics Inc Stock (SWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):